Business
Cybin is using the Flow neuroimaging technology developed by Kernel to create targeted and customized doses of psychedelic compounds for mental health treatment.
The mainstreaming of psychedelics has led to the formation of a new wave of professional organizations to establish best practices for the entheogenic frontier.
Therapies using small amounts of psychedelic compounds may be the future of pain management.
In this week’s Trip Report: Harvard Law students ask if psychedelics can help save America; a new book covers the role of psychedelics in ancient religions; the Canadian parliament is on the clock to decriminalize psychedelics; and more.
The Psychedelic Medicine Association brings together medical professionals to educate and guide each other over emerging science, ethics, and cultural issues in the rapidly developing field of psychedelic medicine.
In this week’s Trip Report, Field Trip Psychedelics becomes the third publicly traded psychedelic company, MindMed & NYU team up to train psychedelic providers and researchers, The New Yorker covers the first NYC psychedelic clinic, and more.
This week’s Trip Report features announcements on Numinus and Field Trip that paint a story of two different approaches and two different challenges, plus AWAKN expands its scientific board, and more.
Mindset aims to create legal compounds that achieve “equal or greater psychedelic effects and therapeutic benefits” than traditional psilocybin.
In this week’s Trip Report, Berkeley’s new psychedelic research center will focus on spiritual and theological investigations alongside scientific research, and COMPASS files to be listed on the NASDAQ.
Objections to a COMPASS psilocybin synthesis patent have been rejected; Usona’s new efficient technique cannot be patented.
